The agreement with NextEra Energy Inc. (NEE) entails wind energy purchases from separate facilities in Oklahoma, Texas and New Mexico, which will increase Xcel Energy�� wind capacity by 14%. The deal includes buying 199 MW from NextEra Energy�� Mammoth Plains Wind Energy Center in Dewey and Blaine counties, Okla., 249 MW from the Palo Duro Wind Energy Center in Hansford and Ochiltree counties, Texas and 250 MW from Infinity Wind Resources/Roosevelt Wind Ranch in Roosevelt County, N.M.
These purchases will reduce fuel costs for customers in Texas and New Mexico. Xcel Energy estimates the deal will lead to savings of $590.4 million over 20 years. The additional contracts are expected to double its wind asset base and will bring the total Texas-New Mexico wind capacity in excess of 2,200 MW.
Top 10 High Tech Companies To Buy Right Now: Illinois Tool Works Inc.(ITW)
Illinois Tool Works Inc. manufactures a range of industrial products and equipment worldwide. The company?s Transportation segment offers metal and plastic components, fasteners, and assemblies; fluids and polymers; fillers and putties; polyester coatings, and patch and repair products; and truck remanufacturing and related parts and service. Its Industrial Packaging segment offers steel and plastic strapping and related tools and equipment; plastic stretch film and related equipment; paper and plastic products that protect goods in transit; and metal jacketing products. The company?s Food Equipment segment provides warewashing, cooking, refrigeration, and food processing equipment; and kitchen exhaust, ventilation, and pollution control systems. Its Power Systems & Electronics segment provides arc welding equipment; metal arc welding consumables; metal solder materials for PC board fabrication; equipment and services for microelectronics assembly; electronic components an d component packaging; and airport ground support equipment. The company?s Construction Products segment offers anchors, fasteners, and related fastening tools for wood, metal, and concrete applications; metal plate truss components, and related equipment and software; and packaged hardware and other products for retail. Its Polymers & Fluids segment provides adhesives, chemical fluids, epoxy and resin-based coating products, hand wipes and cleaners, and pressure-sensitive adhesives and components. The company?s Decorative Surfaces segment offers laminate for furniture, office and retail space, and countertops; and laminate flooring and worktops. In addition, the company offers plastic reclosable packages and bags, and consumables; plastic and metal fasteners, and components; foil and film products; product coding and marking, paint spray, and static and contamination control equipment; and swabs and mats. The company was founded in 1912 and is based in Glenview, Illinois. Advisors' Opinion:
- [By The Part-time Investor]
The following stocks met the criteria in January of 2008 and were put into the initial portfolio:
Abbot Labs (ABT)Advanced data processing (ADP)Associated Banc-Corp (ASBC)Bank of America (BAC)BB&T Corp. (BBT)Bemis Company (BMS)Anheuser Busch (BUD)The Chubb Corporation (CB)Clorox (CLX)Comerica Inc. (CMA)Diebold Inc. (DBD)Emerson Electronics (EMR)First Dollar Corp. (FDO)First Third BanCorp. (FITB)Gannett Co, Inc. (GCI)General Electric (GE)Hershey (HSY)Illinois Tools Works (ITW)Johnson and Johnson (JNJ)Leggett and Platt (LEG)Eli Lilly (LLY)La-Z-Boy (LZB)McDonald's (MCD)Marsh and Ilsley (MI)M&T Bancorp (MTB)PepsiCo (PEP)Pfizer (PFE)Procter & Gamble (PG)Pentair Ltd. (PNR)Regions Financial Corp. (RF)Rohm and Haas (ROH)RPM International (RPM)Sherwin Williams (SHW)Sysco Corp. (SYY)UDR Inc. (UDR)Historical quotes were taken from Yahoo Finance. $10,000 was put into each position, to the nearest whole share, so a total of $349,262.89 was invested. From 1/15/08 through 5/16/13 all dividends were reinvested back into the stock that paid them. If a dividend cut was announced, that stock was sold on the ex-div date of the new, lower dividend.
Top 10 High Tech Companies To Buy Right Now: DAILY MAIL & GENERAL TRUST 'A'ORD NON VTG GBP0.125(DMGT.L)
Daily Mail and General Trust plc operates in the media and information business primarily in the United Kingdom, the rest of Europe, North America, and Australia. It offers various products and services for the quantification and management of catastrophe risk associated with perils, such as earthquakes, hurricanes, windstorms, and terrorist attacks; and business-to-business information to the property, financial, energy, geospatial, and educational recruitment markets. The company also produces business-to-business exhibitions and conferences for the energy, technology, digital marketing, gift, construction, and interior industries with events in North America, the Middle East, Europe, Asia, and Australia. It operates approximately 36 exhibitions and 2 conference businesses in 11 countries. In addition, Daily Mail and General Trust plc publishes approximately 70 magazines, newsletters, and journals, including Euromoney, Institutional Investor, and Metal Bulletin; conducts conferences, seminars, and training courses; and provides electronic information and data covering international finance, metals, and commodities markets. Further, the company operates newspaper companion digital sites; travel, jobs, motors, and property digital businesses; and mobile and television business, as well as provides printing services. Additionally, it publishes approximately 100 publications, including 17 paid-for daily titles, 2 free daily titles, 23 paid-for weeklies, 4 weekly classified titles, 17 monthly magazines, and 40 free weekly newspapers. The company was founded in 1896 and is headquartered in London, the United Kingdom.
Top 10 Growth Stocks To Buy Right Now: Superconductor Technologies Inc.(SCON)
Superconductor Technologies Inc. engages in the development and production of high temperature superconducting (HTS) materials and associated technologies worldwide. The company is leveraging its technologies, including HTS materials and cryogenics, to develop second generation (2G) HTS wire for power applications. Its HTS-based products play a role in emerging power generation, conversion, and distribution applications by enhancing grid reliability and efficiency. The company?s flagship wireless product, SuperLink, combines a specialized filter using patented HTS technology with a proprietary cryogenic cooler and a low-noise amplifier. Its commercial product offerings include SuperLink, a receiver front-end HTS wireless filter system that eliminates out-of-band interference for wireless base stations; AmpLink, a ground-mounted unit for wireless base stations that includes a high-performance amplifier and up to six dual duplexers; and SuperPlex, a multiplexer that provide s low insertion loss and cross-band isolation. The company also grants the U.S. government a royalty-free, non-exclusive, and nontransferable license to use its intellectual property. It sells its products primarily to wireless carriers through direct sales force in the United States, as well as through indirect channels internationally. The company was founded in 1987 and is headquartered in Santa Barbara, California.
Advisors' Opinion:- [By Bryan Murphy]
Just for the record, Superconductor Technologies, Inc. (NASDAQ:SCON) isn't over the hump yet. But, given the likelihood that it could get over the hump with little to no fanfare, now's the time to put SCON on your radar.
Top 10 High Tech Companies To Buy Right Now: Scientific Learning Corporation(SCIL)
Scientific Learning Corporation develops, distributes, and licenses technology worldwide that accelerates learning by enhancing the processing efficiency of the brain. It offers the Fast ForWord language products for elementary learners; the literacy products for adolescent learners; the Fast ForWord reading products, which focus on phonemic awareness, phonics and decoding, spelling, vocabulary, fluency, and comprehension; and Reading Assistant, a software that combines advanced speech verification technology with scientifically-based interventions to help elementary and secondary students strengthen their reading fluency, vocabulary, and comprehension. It also provides Progress Tracker, an Internet-based data analysis and reporting tool, which analyzes student learning results to provide diagnostic and prescriptive intervention information and allows educators to track and report their students? learning progress; Reading Progress Indicator that assesses student?s readi ng skills; BrainSpark products that target learners of age 5 to 13 who are at or above grade level and want to enhance their overall learning potential; and BrainPro targeted at learners who are below grade level. In addition, the company offers KinderSpark series that collects iPad games for children aged 3 to 6 for building readiness skills and excel in learning. Scientific Learning Corporation offers its products to educational institutions, speech and language clinics, learning centers, and parents. The company was founded in 1995 and is headquartered in Oakland, California.
Top 10 High Tech Companies To Buy Right Now: Forest Laboratories Inc (FRX)
Forest Laboratories, Inc. (Forest), incorporated on April 11, 1956, develops, manufactures and sells branded forms of ethical drug products, most of which requires a physician's prescription. The Company also focuses on the development and introduction of new products, including products developed in collaboration with licensing partners. Its products include those developed by the Company and those acquired from other pharmaceutical companies and integrated into its marketing and distribution systems. The Company�� principal products include Lexapro, its selective serotonin reuptake inhibitor (SSRI) for the treatment of major depressive disorder (MDD) in adults and adolescents and generalized anxiety disorder (GAD) in adults; Namenda, its N-methyl-D-Aspartate (NMDA) antagonist for the treatment of moderate and severe Alzheimer's disease; Bystolic, its beta-blocker for the treatment of hypertension; Savella, its selective serotonin and norepinephrine reuptake inhibitor (SNRI) for the management of fibromyalgia and its newest marketed product Teflaro, a broad-spectrum hospital-based injectable cephalosporin antibiotic for the treatment of adults with community-acquired bacterial pneumonia. On April 13, 2011, the Company acquired Clinical Data Inc. (Clinical Data), a specialty pharmaceutical company.
Aclidinium
In June 2011, the Company ahs submitted a New Drug Application (NDA) to the Food and Drug Administration (FDA) for aclidinium (aclidinium bromide), a long-acting antimuscarinic agent developed as an inhaled therapy for the maintenance treatment of chronic obstructive pulmonary disease (COPD). When given by inhalation, aclidinium leads to bronchodilation by inhibiting airway smooth muscle contraction. Aclidinium is rapidly hydrolyzed in human plasma to two major inactive metabolites. Aclidinium is administered to patients using a multi-dose dry powder inhaler (MDPI). This inhaler was designed with a feedback system which, through a ��olored control window��and an a! udible click, helps confirm that the patient has inhaled correctly. It contains multiple doses of aclidinium, includes a visible dose-level indicator, and also incorporates features such as an anti-double dosing mechanism and an end-of-dose lock-out system to prevent use of an empty inhaler.
Linaclotide
Linaclotide is being investigated for the treatment of constipation-predominant irritable bowel syndrome (IBS-C) and chronic constipation (CC). Linaclotide is an agonist of the guanylate cyclase type-C receptor found in the intestine and acts by a mechanism. Linaclotide increases fluid secretions leading to increased bowel movement frequency and reduces abdominal pain. Linaclotide is administered orally but acts locally in the intestine with no measurable systemic exposure at therapeutic doses and is intended for once-daily administration.
Viibryd
As a result of its acquisition of Clinical Data, Inc. (Clinical Data) completed in April 2011, the Company obtained worldwide rights to develop and market Viibryd (vilazodone HCl) a selective serotonin reuptake inhibitor and a 5-HT1A receptor partial agonist developed by Clinical Data for the treatment of adults with major depressive disorder (MDD). Viibryd became available to patients during the June 2011 quarter and was formally launched in the U.S. in late August 2011.
Daliresp
In February 2011, the Company received approval from the United States Food and Drug Administration (FDA) for the marketing of Daliresp (roflumilast). Daliresp is once-daily, orally administered, selective phosphodiesterase 4 (PDE4) enzyme inhibitor, developed by its partner, Nycomed GmbH (Nycomed), as a treatment to reduce the risk of exacerbations in patients with severe chronic obstructive pulmonary disease (COPD) associated with chronic bronchitis and a history of exacerbations.
Namenda
Namenda (memantine HCl) is an N-methyl-D-Aspartate (NMDA) receptor agonist for the treatmen! t of mode! rate and severe Alzheimer�� disease. In June 2010, Namenda XR was approved by the FDA for the treatment of moderate to severe dementia of the Alzheimer�� type. Namenda XR is a 28 milligrams once-daily extended-release formulation of Namenda. The Company has obtained the exclusive rights to develop and market memantine in the United States by license agreement with Merz Pharma GmbH & Co. KgaA (Merz) of Germany, the originator of the product.
Bystolic
Bystolic is a beta-1 selective beta-blocker with vasodilating properties. Bystolic decreases heart rate and myocardial contractility and suppresses rennin activity. The Company licensed exclusive United States and Canadian rights to Bystolic from Mylan Inc. (Mylan).
Savella
Savella (milnacipran HCl) is the Company�� selective serotonin and norepinephrine inhibitor (SNRI) for the management of fibromyalgia. Fibromyalgia is a chronic condition characterized by widespread pain and decreased physical function. The Company licensed the United States and Canadian rights to develop and commercialize Savella from Cypress Bioscience, Inc. (Cypress). Its license agreement includes two patents covering the use of Savella for the management of fibromyalgia.
Teflaro
In October 2010, the Company received marketing approval from the FDA for Teflaro (ceftaroline) for the treatment of adults with community-acquired bacterial pneumonia, including cases caused by Streptococcus pneumoniae bacteremia and with acute bacterial skin and skin structure infections, including cases caused by methicillin-resistant Staphylococcus aureus. Teflaro is a spectrum, hospital-based injectable cephalosporin antibiotic with activity against Gram-positive bacteria and common Gram-negative bacteria. Teflaro is a member of the cephalosporin class of antibiotics. The worldwide rights (excluding Japan) to Teflaro are in-licensed on an exclusive basis from Takeda Pharmaceutical Company (Takeda). Teflaro is als! o covered! by two United States patents that relate to the ceftaroline formulation that expire in 2021 and that may provide additional exclusivity.
Avibactam
Avibactam is designed to be co-administered with select antibiotics to enhance their spectrum of activity. The Company received the exclusive rights to administer avibactam with ceftaroline as a combination product in North America. Avibactam is a beta-lactamase inhibitor designed to be co-administered with select antibiotics to enhance their spectrum of activity by overcoming beta-lactamase-related antibacterial resistance.
Lexapro
Lexapro�� is a SSRI for the treatment of MDD in adults and adolescents and GAD in adults. Lexapro�� (escitalopram oxalate) single isomer version of citalopram HBr, for the treatment of MDD in adults and adolescents and GAD in adults.
Cariprazine
Cariprazine is an oral D2/D3 partial agonist. Cariprazine is also undergoing Phase III trials for schizophrenia and acute mania associated with bipolar depression, bipolar depression and as an adjunct treatment for MDD.
Levomilnacipran
Levomilnacipran is a once-daily, selective norepinephrine and serotonin reuptake inhibitor, two neurotransmitters known to play an essential role in regulating mood, and is being developed for the treatment of MDD.
GRT 6005
In December 2010, the Company entered into a license agreement with Grunenthal GmbH for the co-development and commercialization of GRT 6005 and its follow-on compound GRT 6006, small molecule analgesic compounds being developed by Grunenthal for the treatment of moderate to severe chronic pain. GRT 6005 and GRT 6006 are compounds with pharmacological and pharmacokinetic profiles that may enhance their effect in certain pain conditions. GRT 6005 has completed initial proof-of-concept studies in nociceptive and neuropathic pain with further Phase II studies planned prior to initiation of Phase III s! tudies.
TTP399
In June 2010, the Company entered into a license agreement with TransTech Pharma, Inc. (TransTech) for the development and commercialization of TTP399, a functionally liver selective glucokinase activator (GKA) discovered and developed by TransTech for the treatment of Type II diabetes. Early Phase I testing suggests that pharmacological enhancement of glucokinase activity may lower blood glucose in diabetic patients.
Azimilide
In April 2011, the Company entered into an agreement with Blue Ash Therapeutics, LLC (Blue Ash) pursuant to which it acquired the worldwide rights to azimilide, a class III antiarrhythmic agent developed by Proctor & Gamble Pharmaceuticals. Based on its mechanism of action and results of clinical trials, azimilide was determined to be suited for use in patients with a history of life-threatening ventricular arrhythmias and who have an implantable cardioverter defibrillator. In 2010, the FDA agreed to one additional Phase III study to support a regulatory submission for azimilide in the U.S.
RGH-618
RGH-618 involves a series of compounds that target metabotropic glutamate receptors and are agonists, which represent potential agents for the treatment of anxiety, depression and other central nervous system (CNS) conditions. In March 2012, the Company initiated a Phase I study in healthy volunteers of RGH-618.
Advisors' Opinion:- [By Sean Williams]
So what: Take that phrase "better than expected" with a grain of salt, because when you're a growing biotechnology company with a newly approved drug, Wall Street tends to cut you some slack. For the quarter, Ironwood recorded a 34% decline in revenue to $9.7 million as its loss widened to $0.57 per share. Comparatively speaking, though, this was far better than the $0.70 loss per share on $6.2 million in revenue that the Street had expected. Furthermore, Ironwood backed its full-year sales and marketing expense guidance for its lead drug, Linzess, that it co-markets with Forest Laboratories (NYSE: FRX ) . According to Forest Labs, sales of the drug, which is used to treat irritable bowel syndrome with constipation and chronic idiopathic constipation in adults, totaled $28.8 million for the second quarter.
- [By Johanna Bennett]
Two months since becoming chief executive at Forest Laboratories (FRX), and Brenton Saunders is putting his mark on the drug maker.
On Monday, Forest outlined ��roject Rejuvenate,��a plan to cut costs $500 million by 2016, while scaling back research and development efforts and reducing the company�� work force.
It�� been a common story among big pharmaceutical companies. The industry has grown to depend on acquisitions and licensing deals or partnerships with small drug makers rather than in-house efforts to produce the blockbuster products needed to grow sales and offset revenue lost to generic rivals.
Investors seem to approve. At $55.54, the stock surged 8.2% during afternoon market action.
It was actually a pretty busy day for Forest. Though it restructuring plans attracted the most attention, the company also announced the sale of $1 billion of new debt to help fund $400 million in accelerated stock buybacks as part of a larger $1 billion share repurchase plan and a $250 million deal to acquire exclusive rights to the schizophrenia medication Saphris from Merck & Co. (MRK).
Altogether, it could be quite a boon for Forest�� bottom line. Leerink Swann analyst Seamus Fernandez raised his per share earnings estimate for 2015 and 2016 to $2.89 and $3.24 respectively from the previous $1.87 and $1.19. Fernandez writes:
We see several potential accretive Saphris-like opportunities for FRX particularly as companies like MRK partner or exit cost-intensive primary care/specialty categories (e.g., respiratory, antibiotics/antifungal, cardiology, GI, CNS). Incorporating these changes (and assuming no impact to sales ests of FRX’s existing portfolio), our new DCF valuation increases to $63/shr.
- [By Brian Marckx]
Several large pharma companies have OA drug candidates in various stages of clinical trials including GlaxoSmithKline (GSK), Abbott Laboratories (ABT), and Forest Laboratories (FRX) and would have potentially significant interest in a test such as ILIU's OA test.
Top 10 High Tech Companies To Buy Right Now: Campbell Soup Co (CPB)
Campbell Soup Company (Campbell), incorporated on November 23, 1922, together with its subsidiaries, is a manufacturer and marketer of branded convenience food products. The Company operates in five segments: U.S. Simple Meals; Global Baking and Snacking; International Simple Meals and Beverages; U.S. Beverages; and North America Foodservice. In June 2012, the Company purchased 1300 Admiral Wilson Boulevard in Camden. On August 6, 2012, the Company completed the acquisition of BF Bolthouse Holdco LLC (Bolthouse Farms). In September 2012, Vilmorin & Cie SA acquired the tomato and pepper breeding and sales business of the Company. In June 2013, Campbell Soup Co completed the acquisition of Plum Organics. In August 2013, Campbell Soup Company completed the acquisition of Kelsen Group A/S.
In the United States, Canada and Latin America, the Company�� products are resold to consumers in retail food chains, mass discounters, mass merchandisers, club stores, convenience stores, drug stores, dollar stores and other retail, commercial and non-commercial establishments. In Europe, the Company�� products are resold to consumers in retail food chains, mass discounters, mass merchandisers, club stores, convenience stores and other retail, commercial and non-commercial establishments. In the Asia Pacific region, the Company�� products are resold to consumers through retail food chains, convenience stores and other retail, commercial and non-commercial establishments.
U.S. Simple Meals
The U.S. Simple Meals segment aggregates the operating segments: U.S. Soup and U.S. Sauces. The U.S. Soup retail business includes the products, such as Campbell�� condensed and ready-to-serve soups, and Swanson broth and stocks. The U.S. Sauces retail business includes Pregopasta sauces, Pace Mexican sauces, Campbell�� canned gravies, pasta, and beans, and Swanson canned poultry.
Global Baking and Snacking
The Global Baking and Snacking segment include Pepperi! dge Farm cookies, crackers, bakery and frozen products in the United States retail. It also includes Arnott�� biscuits in Australia and Asia Pacific.
International Simple Meals and Beverages
The International Simple Meals and Beverages segment aggregates the simple meals and beverages operating segments outside of the United States, including Europe, the retail business in Canada, and the businesses in Asia Pacific, Latin America and China. The segment�� operations include Erasco and Heisse Tasse soups in Germany,Liebig and Royco soups in France, Devos Lemmens mayonnaise and cold sauces and Campbell�� and Royco soups in Belgium, and Bla Band soups and sauces in Sweden. In Canada, operations include Habitant and Campbell�� soups, Prego pasta sauces, Pace Mexican sauces, V8 juices and beverages and certain Pepperidge Farm products. In Asia Pacific, operations include Campbell�� soup and stock, Kimball sauces, V8 juices and beverages, Prego pasta sauce and Swanson broths.
U.S. Beverages
The U.S. Beverages segment represents the United States retail beverages business, including V8 juices and beverages, and Campbell�� tomato juice.
North America Foodservice
The North America Foodservice segment represents the distribution of products, such as soup, specialty entrees, beverage products, other prepared foods and Pepperidge Farm products through food service channels in the United States and Canada.
Advisors' Opinion:- [By Paul Ausick]
Big earnings movers: Campbell Soup Co. (NYSE: CPB) is down 3.2% at $43.30. Corinthian Colleges Inc. (NASDAQ: COCO) is down 10.3% at $2.34. JA Solar Holdings Co. Ltd. (NASDAQ: JASO) is down 6.9% at $7.40.
- [By Ben Levisohn]
What is it with food stocks this week? Tyson Foods (TSN) releases earnings on Monday and gains 7.5% through today. Campbell Soup (CPB) releases on Tuesday and falls 6.2%. And now JM Smucker (SJM) releases its own results and has experienced a big move of its own–a plunge.
Top 10 High Tech Companies To Buy Right Now: Ascot Resources Ltd. (AOT.V)
Ascot Resources Ltd., a junior resource company, engages in the acquisition, exploration, evaluation, and development of mineral properties in the North America. Its properties include the Mt. Margaret porphyry copper-molybdenum-gold-silver located to the southwest of Randle Washington in Skamania county; the Premier gold mine located to the north of Stewart, British Columbia; the Dilworth property located to the north of Stewart, north western British Columbia; and the Swamp Point aggregate property, a sand and gravel deposit, located on the Portland Canal in northwestern British Columbia. The company was incorporated in 1986 and is headquartered in Vancouver, Canada.
Top 10 High Tech Companies To Buy Right Now: Wonder Auto Technology Inc.(WATG)
Wonder Auto Technology, Inc., through its subsidiaries, engages in the design, development, manufacture, and marketing of electrical parts, suspension products, and engine components. It offers starters, alternators, engine valves, and tappets in the People?s Republic of China, South Korea, and Brazil, as well as airbags and seatbelts in People?s Republic of China. The company?s products are primarily used in a range of passenger and commercial automobiles. It also manufactures and sells rectifier and regulator products for use in alternators; and various rods and shafts for use in shock absorbers, alternators, and starters. Its customers include automakers, engine manufacturers, and auto parts suppliers. Wonder Auto Technology, Inc. is headquartered in Jinzhou City, the People?s Republic of China.
Top 10 High Tech Companies To Buy Right Now: NxStage Medical Inc.(NXTM)
NxStage Medical, Inc., a medical device company, develops, manufactures, and markets products for the treatment of kidney failure, fluid overload, and related blood treatments and procedures. Its primary product, the NxStage System One, is a portable hemodialysis system used for home hemodialysis and a range of dialysis therapies for chronic home hemodialysis treatment, and the treatment of acute kidney failure and fluid overload. The NxStage System One comprises components, such as The NxStage Cycler, a compact portable electromechanical device; The NxStage Cartridge, a single-use integrated treatment cartridge; and premixed dialysate for hemodialysis applications. The company also sells a line of extracorporeal disposable products for use primarily for in-center dialysis treatments for patients with end-stage renal disease (ESRD); and needles and blood tubing sets primarily to dialysis clinics for the treatment of ESRD. NxStage Medical, Inc. markets its products primaril y to dialysis clinics, nephrologists, and hospitals through distributors and sales representatives in the United States, Mexico, and Europe. The company was formerly known as QB Medical, Inc. and changed its name to NxStage Medical, Inc. NxStage Medical, Inc. founded in 1998 and is headquartered in Lawrence, Massachusetts.
Advisors' Opinion:- [By John Udovich]
Small cap dialysis stock Rockwell Medical Inc (NASDAQ: RMTI) looks set to decline when the market opens after Brean Capital initiated coverage with a sell rating and a price target of $4.00, meaning it might be time to take a closer look at what is going on with the stock along with�the performance of large cap dialysis stocks DaVita Healthcare Partners (NYSE: DVA)�and Fresenius Medical Care (NYSE: FMS) along with small cap dialysis stocks NxStage Medical, Inc (NASDAQ: NXTM).�
Top 10 High Tech Companies To Buy Right Now: Gobimin Inc. (GMN.V)
GobiMin Inc., together with its subsidiaries, engages in the exploration, development, and exploitation of mineral properties primarily in Xinjiang, the People�s Republic of China. It principally explores for gold, copper, and nickel. The company holds a 70% equity interest in the Sawayaerdun gold project covering an area of approximately 1.7094 square kilometers in Xinjiang; and an 8% equity interest in the Yanxi copper property covering an area of approximately 21.67 square kilometers in Xinjiang. The company is based in Toronto, Canada.
No comments:
Post a Comment